Cobimetinib and atezolizumab administered prior to surgery eliminated or shrunk tumors in 70% of patients with melanoma enrolled in the NeoACTIVATE trial. Results were published by Hieken et al in Nature Communications.
2024
Neoadjuvant Immunotherapy Trial Sees High pCR Rates in Stage III Melanoma
A new study suggests a short course of immunotherapy before surgery may significantly improve outcomes in patients with high-risk melanoma.
Rosacea and melanoma strongly linked, big data says
Rosacea patients have more than five times the risk of developing a malignant melanoma and a greater risk of several other systemic conditions, according to researchers.
5-mm Margin May Be Enough for Excising Small Melanoma in Situ
Sun C, Lim A, De’Ambrosis B, et al. Recurrence Rate of Small Melanoma in Situ on Low-Risk Sites Excised With 5-mm Excisional Margin. JAMA Dermatol (2024).